CMS certification 270004
Billings Clinic Hospital
2800 10th Ave N, Billings, MT 59101
Billings Clinic Hospital has a CMS overall rating of 4 out of 5 stars. 71% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 4 and worse on 1. Emergency patients spend a median of 2 h 56 min in its emergency department before leaving (US median 2 h 42 min).
Every figure on this page is published by CMS; we arrange and explain it, and score nothing ourselves.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: 1,380 completed surveys, 27% response rate, Oct 2024 – Sep 2025.
Emergency department
How long emergency patients spent here and how some time-critical care went, from CMS's timely and effective care measures, Oct 2024 – Sep 2025. CMS classes this emergency department's patient volume as high; busier departments tend to have longer times, so the national median for departments of the same volume is shown too. These are medians over a year of visits, not a live wait time.
| Measure | This hospital | MT | US |
|---|---|---|---|
| Median time in the emergency department before leaving Lower is better · 391 visits sampled · US median for EDs of the same volume: 3 h 22 min | 2 h 56 min | 2 h 3 min | 2 h 42 min |
| Median time for psychiatric and mental health patients Lower is better · 39 visits sampled | 2 h 34 min | 2 h 42 min | 4 h 17 min |
| Left before being seen Lower is better · 50,540 patients | 2% | 2% | 2% |
| Severe sepsis and septic shock: all recommended care given Higher is better · 541 patients | 75% | 71% | 65% |
Deaths
How many patients died within 30 days of admission, adjusted by CMS for how sick they were. Lower is better. Data from Jul 2022 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| All patients, hospital-wide 3,780 cases | Too few cases | 3.5% | 3.9% |
| Heart attack 412 cases | Too few cases | 12.3% | 11.9% |
| Heart failure 432 cases | Too few cases | 11.7% | 11.1% |
| Pneumonia 495 cases | Too few cases | 14.5% | 15.2% |
| Stroke 411 cases | Too few cases | 11.4% | 11.9% |
| COPD 153 cases | Too few cases | 9.9% | 8.6% |
| Heart bypass surgery (CABG) 145 cases | Too few cases | 2.4% | 2.4% |
Complications
How often patients had serious complications, most of them after surgery, adjusted for how sick they were. Lower is better. Data from Jul 2022 – Jun 2024.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Serious complications, combined measure | No different | 0.87 likely 0.63 – 1.1 | 1 |
| After hip or knee replacement 172 cases | Too few cases | 3.9% | 4.1% |
| Deaths after a serious but treatable surgical complication 169 cases | No different | 205.34 per 1,000 likely 162.32 per 1,000 – 248.36 per 1,000 | 173.3 per 1,000 |
| Pressure ulcers (bed sores) 7,441 cases | No different | 0.28 per 1,000 likely 0 per 1,000 – 0.78 per 1,000 | 0.63 per 1,000 |
| Collapsed lung caused by a procedure 8,970 cases | No different | 0.11 per 1,000 likely 0 per 1,000 – 0.29 per 1,000 | 0.21 per 1,000 |
| Broken bones from falls in the hospital 9,397 cases | No different | 0.26 per 1,000 likely 0.07 per 1,000 – 0.44 per 1,000 | 0.27 per 1,000 |
| Bleeding or hematoma after surgery 3,294 cases | No different | 3.39 per 1,000 likely 2.19 per 1,000 – 4.6 per 1,000 | 2.34 per 1,000 |
| Kidney injury needing dialysis after surgery 1,574 cases | No different | 1.58 per 1,000 likely 0.24 per 1,000 – 2.92 per 1,000 | 1.67 per 1,000 |
| Breathing failure after surgery 1,489 cases | No different | 9.02 per 1,000 likely 4.12 per 1,000 – 13.91 per 1,000 | 9.42 per 1,000 |
| Blood clots in the lungs or legs after surgery 3,452 cases | No different | 3.43 per 1,000 likely 1.86 per 1,000 – 5 per 1,000 | 3.52 per 1,000 |
| Sepsis after surgery 1,549 cases | No different | 5.09 per 1,000 likely 2.25 per 1,000 – 7.92 per 1,000 | 5.27 per 1,000 |
| Surgical wound splitting open 714 cases | No different | 1.87 per 1,000 likely 0.53 per 1,000 – 3.2 per 1,000 | 1.77 per 1,000 |
| Accidental cut or tear during abdominal surgery 1,912 cases | No different | 0.76 per 1,000 likely 0 per 1,000 – 1.58 per 1,000 | 1.06 per 1,000 |
Infections caught in the hospital
Standardized infection ratio: 1.0 means as many infections as CMS predicted for a hospital like this one. Lower is better. Data from Oct 2024 – Sep 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Bloodstream infections from central lines (CLABSI) | No different | 0.46 likely 0.12 – 1.26 | 1 |
| Urinary tract infections from catheters (CAUTI) | Better | 0.11 likely 0.03 – 0.29 | 1 |
| Surgical site infections after colon surgery | Better | 0 | 1 |
| Surgical site infections after abdominal hysterectomy | No different | 0 | 1 |
| MRSA bloodstream infections | No different | 0.63 likely 0.23 – 1.39 | 1 |
| C. diff intestinal infections | Better | 0.23 likely 0.11 – 0.4 | 1 |
Readmissions and return visits
How often patients had to come back to a hospital after going home. Lower is better. Data from Jul 2023 – Jun 2025.
| Measure | CMS comparison | This hospital | National |
|---|---|---|---|
| Readmitted after a heart attack 455 cases | Too few cases | 14.2% | 14.4% |
| Readmitted after heart failure 510 cases | Too few cases | 19.8% | 21.3% |
| Readmitted after pneumonia 563 cases | Too few cases | 15.8% | 17.3% |
| Readmitted after COPD 180 cases | Too few cases | 20.4% | 20% |
| Readmitted after heart bypass surgery 85 cases | Too few cases | 10.5% | 11% |
| Readmitted after hip or knee replacement 153 cases | Too few cases | 5.2% | 5.8% |
| Days back in hospital after a heart attack 481 cases | Too few cases | -1.6 days per 100 | — |
| Days back in hospital after heart failure 481 cases | Too few cases | 18.5 days per 100 | — |
| Days back in hospital after pneumonia 534 cases | Too few cases | -11.8 days per 100 | — |
| Unplanned visits after an outpatient colonoscopy 2,552 cases | No different | 10.2 per 1,000 likely 7.9 per 1,000 – 13.1 per 1,000 | 13 per 1,000 |
| Hospital admissions during outpatient chemotherapy 396 cases | No different | 9.4 per 100 likely 7.4 per 100 – 11.9 per 100 | 10.7 per 100 |
| ER visits during outpatient chemotherapy 396 cases | No different | 6.5 per 100 likely 4.8 per 100 – 8.6 per 100 | 5.4 per 100 |
| Unplanned visits after outpatient surgery 2,043 cases | No different | 0.9 likely 0.7 – 1.1 | — |
1 more measure had too few cases here to report.
Clinicians registered at this address
286 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 20 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Anesthesiology | 31 |
| Emergency Medicine | 24 |
| Dietitian, Registered | 19 |
| Pediatrics | 18 |
| Hospitalist | 17 |
| Physical Therapist | 12 |
| Diagnostic Radiology | 11 |
| Nurse Anesthetist, Certified Registered | 10 |
| Family | 9 |
| Physician Assistant | 9 |
| Critical Care Medicine | 8 |
| Medical | 8 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $400,733
- 2020 $525,283
- 2021 $812,701
- 2022 $1M
- 2023 $730,011
- 2024 $462,156
- 2025 $752,508
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $254,051 | 5 |
| Speaking, teaching and other services | $48,491 | 85 |
| Space rental and facility fees | $35,400 | 22 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Pfizer INC. | $250,301 | 2 |
| Eli Lilly and Company | $149,486 | 8 |
| Abbvie INC. | $119,346 | 15 |
| Vertex Pharmaceuticals Incorporated | $69,956 | 2 |
| E.R. Squibb & Sons, L.L.C. | $27,406 | 2 |
| Insulet Corporation | $24,825 | 24 |
| Abbott Laboratories | $19,170 | 6 |
| Boston Scientific Corporation | $15,385 | 13 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Partic… ABBVIE INC. · NCT06345339 | $88,858 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN… Eli Lilly and Company · NCT05556512 | $62,422 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) Eli Lilly and Company · NCT04255433 | $54,664 |
| A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis VERTEX PHARMACEUTICALS INCORPORATED | $42,541 |
| M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Ad… ABBVIE INC. | $30,488 |
| A Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis Less Than 12 Months of Age VERTEX PHARMACEUTICALS INCORPORATED | $27,415 |
| Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) Wi… E.R. Squibb & Sons, L.L.C. · NCT06577441 | $26,656 |
| A PHASE 3, RANDOMIZED, MULTICENTER, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY COMPARED WITH PLACEBO IN ADU… Eli Lilly and Company · NCT06297603 | $26,490 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Billings Clinic Hospital
Is Billings Clinic Hospital a good hospital?
Billings Clinic Hospital has a CMS overall rating of 4 out of 5 stars. Of the 27 death, complication, infection and readmission measures CMS could compare, it does better than the nation on 4 and worse on 1. These are hospital-wide results published by CMS; they do not rate individual doctors or departments.
Would patients recommend Billings Clinic Hospital?
71% of patients who answered CMS's national survey would definitely recommend it, against a US average of 71%. The figure comes from 1,380 completed HCAHPS surveys.
How long is the wait in the Billings Clinic Hospital emergency room?
Emergency patients spend a median of 2 h 56 min in its emergency department before leaving (US median 2 h 42 min). Among US emergency departments with high patient volume, like this one, the median is 3 h 22 min. 2% of emergency patients left before being seen (US 2%). These are medians over a year of visits, not a live wait time.
Does Billings Clinic Hospital receive money from drug and device companies?
Drug and device makers reported $752,508 in payments to Billings Clinic Hospital for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.